# EDGAR Filing Document

**Accession Number:** 0001971387
**File Stem:** 0001104659-26-013331
**Filing Date:** 2026-2
**Character Count:** 2448
**Document Hash:** 77efce73dfec0e63dcf53490172e9b0a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-013331.hdr.sgml**: 20260521

**ACCESSION NUMBER**: 0001104659-26-013331

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260211

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Liminatus Pharma, Inc.
- **CENTRAL INDEX KEY:** 0001971387
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 12611 HIDDENCREEK WAY
- **STREET 2:** UNIT C
- **CITY:** CERRITOS
- **STATE:** CA
- **ZIP:** 90703
- **BUSINESS PHONE:** 213-273-5453

**MAIL ADDRESS:**
- **STREET 1:** 12611 HIDDENCREEK WAY
- **STREET 2:** UNIT C
- **CITY:** CERRITOS
- **STATE:** CA
- **ZIP:** 90703

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Iris Parent Holding Corp.
- **DATE OF NAME CHANGE:** 20230328

**Liminatus Pharma, Inc.**

**12611 Hiddencreek Way, Unit C**

**Cerritos, CA 90703**

February 11, 2026

**<u>VIA EDGAR</u>**

U.S. Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

Washington, D.C. 20549

Attention: Mr. Daniel Crawford

---

| | |
|:---|:---|
| **RE:** | **Liminatus Pharma, Inc. (the "Company")** |
|  | **Registration Statement on Form S-1 (File No. 333-293364) (the "Registration Statement")**<br> **<u>Request for Acceleration of Effective Date</u>** |

---

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended (the "Act"), the Company requests that the Securities and Exchange Commission (the "Commission") take appropriate action to cause the Registration Statement to become effective on February 13, 2026 at 9:00 a.m., Eastern Time, or as soon as practicable thereafter, or at such later time as the Company or its counsel may request via telephone call to the staff. In making this acceleration request, the Company acknowledges that it is aware of its obligations under the Act.

---

| | | |
|:---|:---|:---|
| Very truly yours, | Very truly yours, | Very truly yours, |
| **Liminatus Pharma, Inc.** | **Liminatus Pharma, Inc.** | **Liminatus Pharma, Inc.** |
| By: | /s/ Chris Kim | /s/ Chris Kim |
|  | Name: | Chris Kim |
|  | Title: | Chief Executive Officer |

---

cc: Giovanni Caruso, Loeb & Loeb LLP